Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in…


FORT LEE, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a portfolio company of HLB Co., Ltd., today announced the results from a post-hoc analysis of the international CARES-310 study evaluating camrelizumab plus rivoceranib vs. sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of viral and non-viral etiology. The post-hoc analysis will be presented in a poster at the 2025 American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium (ASCO GI) on January 24.

Read the original here:
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in...

Related Posts